We are live on
!
Find out more
KK
Kotler Kevin Portfolio holdings
AUM
$427M
This Fund
S&P 500
This Quarter
Est. Return
+61.7%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$427M
AUM Growth
–
Cap. Flow
+$119M
Cap. Flow
% of AUM
27.77%
Top 10 Holdings %
Top 10 Hldgs %
89.56%
Holding
38
New
38
Increased
–
Reduced
–
Closed
–
Avg Time Held Equity + Options
0
quarters
Top 10 Avg Time Held Equity + Options
0
quarters
Top 20 Avg Time Held Equity + Options
0
quarters
Avg Time Held Equity only
0
quarters
Top 10 Avg Time Held Equity only
0
quarters
Top 20 Avg Time Held Equity only
0
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AngioDynamics
ANGO
|
+$21.2M |
| 2 |
Aurinia Pharmaceuticals
AUPH
|
+$17.4M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$14.4M |
| 4 |
Neuropace
NPCE
|
+$8.44M |
| 5 |
Omeros
OMER
|
+$7.8M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 68.39% |
| 2 | Healthcare | 29.66% |
| 3 | Industrials | 1.36% |
| 4 | Consumer Discretionary | 0.53% |
| 5 | Financials | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$833B
| $239M | 55.83% |
+350,000
| New | +$237M |
2025 Q4
0 quarters
|
|
2
PUT
Invesco QQQ Trust
QQQ
$507B
| $30.7M | 7.18% |
+50,000
| New | +$30.7M |
2025 Q4
0 quarters
|
|
|
3
AngioDynamics
ANGO
$484M
| $22M | 5.15% |
+1,713,789
| New | +$21.2M |
2025 Q4
0 quarters
|
|
|
4
Aurinia Pharmaceuticals
AUPH
$2.22B
| $19.5M | 4.57% |
+1,224,846
| New | +$17.4M |
2025 Q4
0 quarters
|
|
|
AVDL
5
CALL
DELISTED
Avadel Pharmaceuticals
AVDL
| $19M | 4.43% |
+879,400
| New | +$17.1M |
2025 Q4
0 quarters
|
|
|
AVDL
6
DELISTED
Avadel Pharmaceuticals
AVDL
| $16M | 3.74% |
+741,343
| New | +$14.4M |
2025 Q4
0 quarters
|
|
|
7
Omeros
OMER
$1.44B
| $15.6M | 3.64% |
+905,635
| New | +$7.8M |
2025 Q4
0 quarters
|
|
|
8
Neuropace
NPCE
$435M
| $9.75M | 2.28% |
+631,468
| New | +$8.44M |
2025 Q4
0 quarters
|
|
9
MediWound
MDWD
$162M
| $6.23M | 1.46% |
+337,236
| New | +$6.16M |
2025 Q4
0 quarters
|
|
10
Axogen
AXGN
$2.12B
| $5.5M | 1.29% |
+168,000
| New | +$4.13M |
2025 Q4
0 quarters
|
|
11
Integra LifeSciences
IART
$1.05B
| $5.31M | 1.24% |
+427,445
| New | +$5.68M |
2025 Q4
0 quarters
|
|
12
Aclaris Therapeutics
ACRS
$564M
| $5.13M | 1.2% |
+1,705,929
| New | +$4.31M |
2025 Q4
0 quarters
|
|
13
Vertical Aerospace
EVTL
$88.1M
| $5.01M | 1.17% |
+939,705
| New | +$4.76M |
2025 Q4
0 quarters
|
|
14
OraSure Technologies
OSUR
$269M
| $4.36M | 1.02% |
+1,801,446
| New | +$4.74M |
2025 Q4
0 quarters
|
|
|
15
CALL
Omeros
OMER
$1.44B
| $3.79M | 0.89% |
+218,700
| New | +$1.88M |
2025 Q4
0 quarters
|
|
|
LKFT
16
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.95B
| $2.94M | 0.69% |
+90,000
| New | +$2.91M |
2025 Q4
0 quarters
|
|
17
Eli Lilly
LLY
$1.05T
| $2.15M | 0.5% |
+2,000
| New | +$1.91M |
2025 Q4
0 quarters
|
|
18
Cerus
CERS
$464M
| $2.08M | 0.49% |
+1,011,614
| New | +$1.75M |
2025 Q4
0 quarters
|
|
19
Nike
NKE
$51.6B
| $2.04M | 0.48% |
+32,000
| New | +$2.09M |
2025 Q4
0 quarters
|
|
|
TECX
20
Tectonic Therapeutic
TECX
$456M
| $1.67M | 0.39% |
+80,000
| New | +$1.49M |
2025 Q4
0 quarters
|
|
|
CLYM
21
Climb Bio
CLYM
$632M
| $1.6M | 0.37% |
+400,000
| New | +$961K |
2025 Q4
0 quarters
|
|
22
Treace Medical Concepts
TMCI
$257M
| $1.16M | 0.27% |
+474,365
| New | +$2.06M |
2025 Q4
0 quarters
|
|
23
TriSalus Life Sciences
TLSI
$250M
| $1.01M | 0.24% |
+145,200
| New | +$813K |
2025 Q4
0 quarters
|
|
24
DexCom
DXCM
$31.7B
| $996K | 0.23% |
+15,000
| New | +$970K |
2025 Q4
0 quarters
|
|
25
Vanda Pharmaceuticals
VNDA
$276M
| $882K | 0.21% |
+100,000
| New | +$550K |
2025 Q4
0 quarters
|
|
Similar funds
STS
MCP
JHCM
MG
AWIRL
VW
DP
EP
Kotler Kevin's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for Kotler Kevin, which disclosed 38 positions worth $427M. Its ten largest holdings account for 90% of the portfolio.
Its largest position is AngioDynamics: 1,713,789 shares worth $22M.
By sector, the portfolio is most concentrated in Miscellaneous at 68% of assets, followed by Healthcare and Industrials.
- Kotler Kevin's largest Q4 2025 buy was AngioDynamics: 1,713,789 shares worth $22M.
- Kotler Kevin's ten largest holdings make up 90% of its $427M portfolio in Q4 2025.
- Kotler Kevin disclosed 38 positions in Q4 2025, its first 13F filing on record.
Based on Kotler Kevin's 13F filing for Q4 2025, filed 17 Feb 2026.